Hamburg to Take Hold of FDA

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Senate confirmed late Monday night Dr. Margaret A. Hamburg, 53, to lead the US Food and Drug Administration.

The Senate confirmed late Monday night Dr. Margaret A. Hamburg, 53, to lead the US Food and Drug Administration. Her confirmation comes two months after President Obama nominated her for the job. Hamburg has served as New York City’s acting health commissioner, US Department of Health and Human Services (HHS) assistant secretary for planning and evaluation, and more recently, a senior scientist at Nuclear Threat Initiative (NTI).

In a May 7, 2009, statement, US Senator Ted Kennedy (D-MA) described Dr. Hamburg as a “widely respected for her expertise in community health, bio-defense, and nuclear, biological, and chemical preparedness.” He went on to say that Dr. Hamburg “will face many challenges as FDA Commissioner, and she is obviously well-qualified to deal with them.” Swine flu, contaminated food products, and drug supply chains will be among her first challenges.

Hamburg’s confirmation, which was unanimous, completes the HHS food and drug leadership circle, with former Kansas Governor Kathleen Sebelius serving as new HHS Secretary and Joshua Sharfstein, former Baltimore health commissioner, serving as principal deputy commissioner of FDA. Hamburg will be sworn in as commissioner this week.

See related PharmTech blog posts

Obama’s Choice of Hamburg to Lead FDA: Good or Bad?

Has the Time Come to Divide FDA?

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes